Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

NEXT STORY
Liposome Drug Delivery Market Size Worth $6,992.95 Million, Globally, by 2027 at 8.8% CAGR – Exclusive Report by The Insight Partners
PREV STORY
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

VBL Therapeutics Announces the Appointments of Susan Kelley and David Hastings to Its Board of Directors

Senior pharmaceutical executives with extensive experience in immuno-oncology, drug development, commercializing oncology medications and ...

author_avatar
NASDAQ Market News

Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

Initiated final testing of safety and efficacy in non-human primates (NHP) for our lead ...

author_avatar
NASDAQ Market News

Elekta och Philips installerar MRI-styrd linjäraccelerator vid Netherlands Cancer Institute

Installationen visar på fortskridandet av det globala konsortiets arbete för förbättrade behandlingsresultat genom klinisk ...

author_avatar
NASDAQ Market News